Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 Symptoms 9
2.1.1 Early Gastric Cancer 9
2.1.2 Early Esophageal Cancer 10
2.1.3 Advanced Gastric or Esophageal Cancer 10
2.2 Etiology 10
2.2.1 Esophageal Cancer 10
2.2.2 Gastric Cancer 11
2.3 Epidemiology 11
2.4 Pathophysiology 12
2.5 Diagnosis 13
2.6 Prognosis and Disease Staging 13
2.7 Treatment Options 16
2.7.1 Chemotherapy 16
2.7.2 Targeted Therapies 16
2.7.3 Treatment Guidelines 17
2.7.4 Resistance to Pharmacological Therapies 19
3 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Marketed Products 20
3.1 Herceptin (Trastuzumab) – Hoffman La Roche 20
4 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Developmental Pipeline 22
4.1 Gastric Cancer 22
4.1.1 Overall Pipeline 22
4.1.2 Molecular Targets 24
4.1.3 Clinical Trials 26
4.1.4 Conclusion 33
4.2 Esophageal Cancer 34
4.2.1 Overall Pipeline 34
4.2.2 Molecular Targets 36
4.2.3 Clinical Trials 37
4.2.4 Conclusion 43
4.3 Key Late-Stage Pipeline Products 43
4.3.1 AMG 102 (rilotumumab) – Amgen 43
4.3.2 IMC-1121B (Ramucirumab) – Eli Lilly and Company 43
4.3.3 Theraloc (Nimotuzumab) – YM Biosciences 44
4.3.4 MetMAb (Onartuzumab) – F. Hoffmann-La Roche 44
4.3.5 Perjeta (pertuzumab) – F. Hoffmann-La Roche 44
4.3.6 Kadcyla (ado-trastuzumab emtansine) – F. Hoffmann-La Roche 45
4.4 Conclusion 46
5 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Market Forecast to 2019 47
5.1 Gastric Cancer 48
5.1.1 Global 48
5.1.2 US 51
5.1.3 Canada 53
5.1.4 Europe 55
5.1.5 Japan 58
5.2 Esophageal Cancer 60
5.2.1 Global 60
5.2.2 US 62
5.2.3 Canada 64
5.2.4 Europe 66
5.2.5 Japan 69
5.3 Drivers and Barriers 70
5.3.1 Drivers 70
5.3.2 Barriers 72
6 Deals and Strategic Consolidations 74
6.1 Licensing Agreements 74
6.1.1 Gastric Cancer 74
6.1.2 Esophageal Cancer 77
6.2 Co-Development Agreements 77
6.2.1 Gastric Cancer 77
6.2.2 Esophageal Cancer 78
7 Appendix 79
7.1 Market Definitions 79
7.2 Abbreviations 79
7.3 References 80
7.4 All Pipeline Products, by Stage of Development 84
7.4.1 Gastric Cancer 84
7.4.2 Esophageal Cancer 93
7.5 Tabular Forecast Data 97
7.5.1 Gastric Cancer 97
7.5.2 Esophageal Cancer 100
7.6 Research Methodology 102
7.6.1 Coverage 102
7.6.2 Secondary Research 103
7.6.3 Therapeutic Landscape 103
7.6.4 Epidemiology-Based forecasting 103
7.6.5 Market Size by Geography 105
7.6.6 Geographical Landscape 106
7.6.7 Pipeline Analysis 106
7.6.8 Competitive Landscape 106
7.6.9 Expert Panel Validation 106
7.7 Contact Us 106
7.8 Disclaimer 106